Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.0059 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.2533 |
Open* | 0.294 |
1-Year Change* | -72.26% |
Day's Range* | 0.2635 - 0.312 |
52 wk Range | 0.05-1.45 |
Average Volume (10 days) | 70.85K |
Average Volume (3 months) | 2.84M |
Market Cap | 3.59M |
P/E Ratio | -100.00K |
Shares Outstanding | 44.57M |
Revenue | 22.36M |
EPS | -0.18 |
Dividend (Yield %) | N/A |
Beta | 0.97 |
Next Earnings Date | May 20, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 18, 2023 | 0.3090 | 0.0041 | 1.34% | 0.3049 | 0.3209 | 0.2601 |
Jul 17, 2023 | 0.2533 | -0.0607 | -19.33% | 0.3140 | 0.3166 | 0.2491 |
Jul 14, 2023 | 0.3153 | -0.0302 | -8.74% | 0.3455 | 0.3455 | 0.3090 |
Jul 13, 2023 | 0.3490 | 0.0454 | 14.95% | 0.3036 | 0.3588 | 0.2790 |
Jul 12, 2023 | 0.3289 | -0.0499 | -13.17% | 0.3788 | 0.3987 | 0.3153 |
Jul 11, 2023 | 0.2606 | 0.0114 | 4.57% | 0.2492 | 0.2669 | 0.2490 |
Jul 10, 2023 | 0.2617 | 0.0227 | 9.50% | 0.2390 | 0.2638 | 0.2390 |
Jul 7, 2023 | 0.2491 | 0.0257 | 11.50% | 0.2234 | 0.2502 | 0.2234 |
Jul 6, 2023 | 0.2263 | 0.0046 | 2.07% | 0.2217 | 0.2321 | 0.2213 |
Jul 5, 2023 | 0.2272 | 0.0080 | 3.65% | 0.2192 | 0.2332 | 0.2192 |
Jul 3, 2023 | 0.2148 | 0.0006 | 0.28% | 0.2142 | 0.2259 | 0.2142 |
Jun 30, 2023 | 0.2144 | -0.0025 | -1.15% | 0.2169 | 0.2169 | 0.1993 |
Jun 29, 2023 | 0.2129 | 0.0037 | 1.77% | 0.2092 | 0.2167 | 0.2092 |
Jun 28, 2023 | 0.2116 | -0.0276 | -11.54% | 0.2392 | 0.2392 | 0.2092 |
Jun 27, 2023 | 0.2413 | -0.0088 | -3.52% | 0.2501 | 0.2531 | 0.2345 |
Jun 26, 2023 | 0.2492 | -0.0099 | -3.82% | 0.2591 | 0.2591 | 0.2491 |
Jun 23, 2023 | 0.2597 | 0.0051 | 2.00% | 0.2546 | 0.2603 | 0.2492 |
Jun 22, 2023 | 0.2566 | -0.0025 | -0.96% | 0.2591 | 0.2591 | 0.2541 |
Jun 21, 2023 | 0.2565 | 0.0043 | 1.70% | 0.2522 | 0.2601 | 0.2501 |
Jun 20, 2023 | 0.2552 | -0.0014 | -0.55% | 0.2566 | 0.2671 | 0.2516 |
Aridis Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, May 20, 2024 | ||
Time (UTC) 20:00 | Country US
| Event Q4 2023 Aridis Pharmaceuticals Inc Earnings Release Q4 2023 Aridis Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Thursday, June 6, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Aridis Pharmaceuticals Inc Earnings Release Q1 2024 Aridis Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 3.091 | 1.535 | 1 | 1.022 | 2.757 |
Revenue | 3.091 | 1.535 | 1 | 1.022 | 2.757 |
Cost of Revenue, Total | |||||
Gross Profit | |||||
Total Operating Expense | 33.084 | 43.524 | 23.401 | 30.109 | 26.874 |
Selling/General/Admin. Expenses, Total | 7.161 | 7.31 | 6.445 | 6.026 | 3.874 |
Research & Development | 25.923 | 36.936 | 16.956 | 24.083 | 23 |
Operating Income | -29.993 | -41.989 | -22.401 | -29.087 | -24.117 |
Interest Income (Expense), Net Non-Operating | -0.121 | -0.245 | 0.068 | -0.594 | 0.38 |
Other, Net | -0.257 | 0.041 | 1.632 | ||
Net Income Before Taxes | -30.371 | -42.193 | -22.333 | -29.681 | -22.105 |
Net Income After Taxes | -30.371 | -42.193 | -22.333 | -29.681 | -22.105 |
Net Income Before Extra. Items | -30.371 | -42.193 | -22.333 | -29.681 | -22.105 |
Net Income | -30.371 | -42.193 | -22.333 | -29.681 | -22.105 |
Total Adjustments to Net Income | 0 | -4.127 | 0 | -1.357 | |
Income Available to Common Excl. Extra. Items | -30.371 | -46.32 | -22.333 | -29.681 | -23.462 |
Income Available to Common Incl. Extra. Items | -30.371 | -46.32 | -22.333 | -29.681 | -23.462 |
Diluted Net Income | -30.371 | -46.32 | -22.333 | -29.681 | -23.462 |
Diluted Weighted Average Shares | 18.7773 | 12.2916 | 9.16874 | 8.45828 | 8.10729 |
Diluted EPS Excluding Extraordinary Items | -1.61743 | -3.76843 | -2.43578 | -3.50911 | -2.89394 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | 10.4716 | -3.82717 | -2.43578 | -3.50911 | -2.89394 |
Unusual Expense (Income) | 0 | -0.722 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 19.647 | 1.082 | 1.213 | 0.399 | 0.292 |
Revenue | 19.647 | 1.082 | 1.213 | 0.399 | 0.292 |
Total Operating Expense | 5.978 | 7.345 | 8.633 | 7.811 | 8.029 |
Selling/General/Admin. Expenses, Total | 1.31 | 1.814 | 1.626 | 1.693 | 1.681 |
Research & Development | 4.668 | 5.531 | 7.007 | 6.118 | 6.348 |
Operating Income | 13.669 | -6.263 | -7.42 | -7.412 | -7.737 |
Interest Income (Expense), Net Non-Operating | 0.003 | 0.027 | 0.146 | -0.027 | 0.008 |
Other, Net | -1.528 | -0.58 | 0.887 | -0.8 | -0.25 |
Net Income Before Taxes | 12.144 | -6.816 | -6.387 | -8.239 | -7.979 |
Net Income After Taxes | 12.144 | -6.816 | -6.387 | -8.239 | -7.979 |
Net Income Before Extra. Items | 12.144 | -6.816 | -6.387 | -8.239 | -7.979 |
Net Income | 12.144 | -6.816 | -6.387 | -8.239 | -7.979 |
Total Adjustments to Net Income | 0 | 0 | 0 | ||
Income Available to Common Excl. Extra. Items | 12.144 | -6.816 | -6.387 | -8.239 | -7.979 |
Income Available to Common Incl. Extra. Items | 12.144 | -6.816 | -6.387 | -8.239 | -7.979 |
Diluted Net Income | 12.144 | -6.816 | -6.387 | -8.239 | -7.979 |
Diluted Weighted Average Shares | 36.573 | 30.4149 | 22.0046 | 17.7016 | 17.7016 |
Diluted EPS Excluding Extraordinary Items | 0.33205 | -0.2241 | -0.29026 | -0.46544 | -0.45075 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.33205 | -0.2241 | 8.52609 | -0.46544 | 1.41349 |
Unusual Expense (Income) | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 11.626 | 24.39 | 12.755 | 25.837 | 28.347 |
Cash and Short Term Investments | 4.876 | 18.098 | 8.232 | 20.897 | 24.237 |
Cash & Equivalents | 4.876 | 18.098 | 8.232 | 20.897 | 24.237 |
Total Receivables, Net | 1.24 | 0.237 | 0.368 | 0.413 | 1.66 |
Accounts Receivable - Trade, Net | 1 | 0 | 1.66 | ||
Prepaid Expenses | 3.341 | 2.7 | 2.182 | 2.99 | 2.45 |
Total Assets | 14.695 | 26.796 | 15.117 | 27.967 | 31.611 |
Property/Plant/Equipment, Total - Net | 2.147 | 1.357 | 1.258 | 1.006 | 1.271 |
Property/Plant/Equipment, Total - Gross | 4.19 | 2.942 | 2.413 | 1.829 | 1.762 |
Accumulated Depreciation, Total | -2.043 | -1.585 | -1.155 | -0.823 | -0.491 |
Intangibles, Net | 0.017 | 0.022 | 0.027 | 0.032 | 0.038 |
Other Long Term Assets, Total | 0.827 | 0.931 | 0.987 | 0.557 | 0.995 |
Total Current Liabilities | 36.898 | 33.348 | 22.44 | 19.331 | 5.297 |
Accounts Payable | 6.089 | 5.24 | 1.886 | 1.755 | 2.331 |
Accrued Expenses | 10.102 | 6.464 | 1.33 | 2.974 | 2.944 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 20.188 | 20.948 | 18.785 | 14.602 | 0.022 |
Total Liabilities | 38.927 | 39.906 | 23.798 | 24.331 | 5.297 |
Total Long Term Debt | 0 | 5.282 | 0.276 | 0 | 0 |
Other Liabilities, Total | 2.029 | 1.276 | 1.082 | 5 | 0 |
Total Equity | -24.232 | -13.11 | -8.681 | 3.636 | 26.314 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.003 | 0.002 | 0.001 | 0.001 | 0.001 |
Additional Paid-In Capital | 166.38 | 152.183 | 114.42 | 104.404 | 97.401 |
Retained Earnings (Accumulated Deficit) | -195.666 | -165.295 | -123.102 | -100.769 | -71.088 |
Total Liabilities & Shareholders’ Equity | 14.695 | 26.796 | 15.117 | 27.967 | 31.611 |
Total Common Shares Outstanding | 27.0335 | 17.7016 | 10.0657 | 8.91846 | 8.10476 |
Long Term Investments | 0 | 0.009 | 0.96 | ||
Other Current Assets, Total | 2.169 | 3.355 | 1.973 | 1.537 | |
Note Receivable - Long Term | 0.078 | 0.096 | 0.09 | 0.526 | |
Current Port. of LT Debt/Capital Leases | 0.519 | 0.696 | 0.439 | ||
Long Term Debt | 0 | 5.282 | 0.276 | ||
Other Equity, Total | 5.051 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 4.11 | 3.884 | 6.566 | 11.626 | 8.635 |
Cash and Short Term Investments | 0.035 | 0.019 | 1.32 | 4.876 | 1.886 |
Cash & Equivalents | 0.035 | 0.019 | 1.32 | 4.876 | 1.886 |
Total Receivables, Net | 0.517 | 0.3 | 0.1 | 1.24 | 0.248 |
Prepaid Expenses | 3.558 | 3.565 | 3.16 | 3.341 | 3.768 |
Other Current Assets, Total | 0 | 0 | 1.986 | 2.169 | 2.733 |
Total Assets | 6.534 | 6.482 | 9.434 | 14.695 | 12.12 |
Property/Plant/Equipment, Total - Net | 1.584 | 1.757 | 1.947 | 2.147 | 2.506 |
Property/Plant/Equipment, Total - Gross | 3.832 | 3.947 | 4.075 | 4.19 | 4.45 |
Accumulated Depreciation, Total | -2.248 | -2.19 | -2.128 | -2.043 | -1.944 |
Intangibles, Net | 0.013 | 0.014 | 0.015 | 0.017 | 0.018 |
Note Receivable - Long Term | 0 | 0 | 0.078 | 0.078 | 0.078 |
Other Long Term Assets, Total | 0.827 | 0.827 | 0.828 | 0.827 | 0.883 |
Total Current Liabilities | 17.482 | 20.394 | 35.431 | 36.898 | 42.277 |
Accounts Payable | 8.82 | 10.967 | 6.159 | 6.089 | 12.025 |
Accrued Expenses | 8.267 | 9.024 | 9.958 | 10.102 | 9.02 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0.208 | 0.519 | 0.831 |
Other Current Liabilities, Total | 0.395 | 0.403 | 19.106 | 20.188 | 20.401 |
Total Liabilities | 18.336 | 21.396 | 37.316 | 38.927 | 47.943 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 3.499 |
Long Term Debt | 0 | 3.499 | |||
Other Liabilities, Total | 0.854 | 1.002 | 1.885 | 2.029 | 2.167 |
Total Equity | -11.802 | -14.914 | -27.882 | -24.232 | -35.823 |
Common Stock | 0.005 | 0.004 | 0.004 | 0.003 | 0.002 |
Additional Paid-In Capital | 170.827 | 168.894 | 168.684 | 166.38 | 153.454 |
Retained Earnings (Accumulated Deficit) | -190.421 | -190.338 | -202.482 | -195.666 | -189.279 |
Total Liabilities & Shareholders’ Equity | 6.534 | 6.482 | 9.434 | 14.695 | 12.12 |
Total Common Shares Outstanding | 44.574 | 36.0775 | 36.0775 | 27.0335 | 17.7016 |
Accounts Receivable - Trade, Net | 0.417 | 0.2 | 0 | 1 | |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Other Equity, Total | 7.787 | 6.526 | 5.912 | 5.051 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -30.371 | -42.193 | -22.333 | -29.681 | -22.105 |
Cash From Operating Activities | -29.127 | -22.936 | -20.476 | -8.159 | -24.271 |
Cash From Operating Activities | 0.487 | 0.435 | 0.337 | 0.338 | 0.283 |
Non-Cash Items | 2.056 | 8.305 | 2.137 | 2.961 | 0.066 |
Cash Taxes Paid | 0.019 | 0.002 | 0.002 | 0.002 | 0.002 |
Cash Interest Paid | |||||
Changes in Working Capital | -1.299 | 10.517 | -0.617 | 18.223 | -2.515 |
Cash From Investing Activities | -0.082 | -0.53 | -0.367 | -0.174 | -1.677 |
Capital Expenditures | -0.082 | -0.53 | -0.367 | -0.174 | -0.677 |
Cash From Financing Activities | 14.782 | 34.72 | 8.678 | 4.993 | 25.089 |
Issuance (Retirement) of Stock, Net | 12.612 | 29.72 | 7.963 | 4.993 | 25.089 |
Issuance (Retirement) of Debt, Net | 5 | 5 | 0.715 | ||
Net Change in Cash | -14.427 | 11.254 | -12.165 | -3.34 | -0.859 |
Other Investing Cash Flow Items, Total | 0 | -1 | |||
Financing Cash Flow Items | -2.83 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -6.816 | -30.371 | -23.984 | -15.745 | -7.766 |
Cash From Operating Activities | -4.002 | -29.127 | -20.57 | -16.305 | -10.166 |
Cash From Operating Activities | 0.087 | 0.487 | 0.387 | 0.262 | 0.131 |
Non-Cash Items | -0.011 | 2.056 | 2.659 | 1.487 | 0.833 |
Cash Taxes Paid | 0.001 | 0.019 | 0.005 | 0.002 | 0 |
Changes in Working Capital | 2.738 | -1.299 | 0.368 | -2.309 | -3.364 |
Cash From Investing Activities | 0 | -0.082 | -0.033 | -0.033 | -0.021 |
Capital Expenditures | 0 | -0.082 | -0.033 | -0.033 | -0.021 |
Cash From Financing Activities | 0.263 | 14.782 | 3.75 | 4.304 | 4.443 |
Issuance (Retirement) of Stock, Net | 2.059 | 12.612 | 0 | 0 | 0 |
Net Change in Cash | -3.739 | -14.427 | -16.853 | -12.034 | -5.744 |
Issuance (Retirement) of Debt, Net | 0 | 5 | 5 | 5 | 5 |
Financing Cash Flow Items | -1.796 | -2.83 | -1.25 | -0.696 | -0.557 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aridis Pharmaceuticals, Inc. Company profile
About Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).
Industry: | Bio Therapeutic Drugs |
983 University Avenue, Bldg. B
LOS GATOS
CALIFORNIA 95032
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com